Global Antifungal Agents Market by Drug Types (Echinocandins, Azoles, Polyenes, and Allylamines) by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis) by Applications (Topical Antifungal Agents, Oral Drugs) by Geography Analysis 2017-2025
KEY FINDINGS The “Global Antifungal Agents Market” is projected to grow from $6400 million in 2016 to $12924 million by 2025. Due to increasing of various fungal infections awareness among people is boosting the antifungal agents market.
Browse Complete Report with TOC @ https://www.inkwoodresearch.com/reports/global-antifungal-agents-market-forecast-2017-2025/
MARKET INSIGHTS The antifungal agents market is segmented on the basis of drug types, therapeutic indications, applications, and geography. The antifungal agents market on the basis of drug types is segmented into echinocandins, azoles, polyenes, allylamines and others. On the basis of therapeutic indications, aspergillosis, dermatophytosis, candidiasis and others. The antifungal agents application market is segregated into topical antifungal agents and oral drugs. The antifungal agents on the basis of geography are segmented into Asia-Pacific, Europe, Rest of the World and North America. Poor hygiene habits and the rising awareness about the antifungal agents for treatment is one of the major drivers for the antifungal agents market. The healthcare policies and programs by government and the development of drug resistance are preeminent drivers for the growth of antifungal agents market.
REGIONAL INSIGHTS North America antifungal agents market holds the largest market share in the global antifungal agents market in 2016. The rise in the incidence of fungal infections and the developing antifungal biopharmaceuticals in the region is driving the market. Asia-Pacific is projected to be the fastest-growing region for the global antifungal agents market. Europe antifungal agents market is estimated to grow during the forecast period.
COMPETITIVE INSIGHTS The leading market players for Antifungal agents market are Vertex Pharmaceuticals, Teva pharmaceuticals, Sanofi-Aventis, Pfizer, Novartis, Merck & co, Kramer laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, Bayer healthcare, Astellas Pharma Inc., Arbor pharmaceuticals Inc., Abbott laboratories, and 3 Baxter.